Influence of Motor Proteins on Muscle Atrophy in Cancer Patients

NCT ID: NCT03551990

Last Updated: 2018-06-11

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 420 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-31
• Study Completion Date: 2022-06-30

Brief Summary

The aim of the study is to investigate the effect of exercise in form of whole-body electromyostimulation (WB-EMS) on early tumor-induced muscular dysfunction. It is anticipated to gain detailed knowledge about composition and metabolism of skeletal muscle cells, and single muscle fiber functionality. To determine key factors leading to impaired force generation and thus decreased muscle strength in cancer patients who are suspected to develop or already show early signs of tumor cachexia is crucial for the establishment of effective cancer treatment. Comparative analysis of skeletal muscle biopsies taken from the abdomen of patients during indicated surgeries will be conducted. The patients will be allocated to the following study groups: a) Study group 1: Patients without cancer, b) Study group 2: Patients with solid tumors who did not perform physical training and c) Study group 3: Patients with solid tumors who executed physical training in form of WB-EMS. The investigation can help to understand skeletal muscle physiology under exercise and to get a better insight into the effects of physical training on early-stage muscle atrophy, both on cellular and molecular level. Initially, it is planned to identify the inflammation and nutrition status of the patients, and to determine skeletal muscle strength. It is anticipated to explore muscle protein composition, particularly myosin to actin ratio and their interaction. Biochemical analysis and the examination of the cellular ultra-structure should enhance the knowledge about the key mechanisms controlling the contractile apparatus of single muscle fibers in order to determine the quality of muscle force. Taken together, these investigations will help to better understand muscle atrophy in advanced cancer patients, and might support the development of targeted anti-cachectic therapies, that can be applied already in early phases of the tumor disease to significantly improve the patients' prognosis and their quality of life.

Conditions

Cancer; Muscle Atrophy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Control group; patients without a tumor disease, surgery

Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis

Group Type: NO_INTERVENTION

No interventions assigned to this group

Control group; tumor patients, surgery

Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis

Group Type: NO_INTERVENTION

No interventions assigned to this group

Intervention group; tumor patients, WB-EMS, surgery

Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis

Group Type: EXPERIMENTAL

whole-body electromyostimulation WB-EMS

Intervention Type: PROCEDURE

Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.

Interventions

whole-body electromyostimulation WB-EMS

Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patients ≥ 18 years
• Solid pancreatic, colorectal, esophageal, gastric and liver tumors under oncological treatment
• Karnofsky performance index between 50 and 100
• Loss of body weight (≥ 2 % and < 5 %, weight before the illness and at study entry)
• Distinct decrease in muscle force
• Indication for surgery proximal to the M. rectus abdominis
• Intervention Group must have an at least 8-week waiting period until the surgery (to conduct WB-EMS)

Exclusion Criteria

• Participation in other nutrition or exercise intervention studies
• Study-independent exercise more than once a week
• Ingestion of anabolic or dietary supplements
• Occurrence of heavy cardio-vascular events
• Epilepsy and other severe neurological disorders
• Skin lesions in the area of the electrodes
• Conductive materials or electronical implants in the body (that do not allow electromyostimulation)
• Pregnancy
• Chronic diseases (e.g. HIV or Hepatitis C/D/E)
• Rejection of a muscle biopsy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Erlangen-Nürnberg Medical School

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hector-Center for Nutrition, Exercise and Sports

Erlangen, Bavaria, Germany

Site Status: RECRUITING

Countries

Germany

Facility Contacts

Yurdagül Zopf, Prof. Dr. med.

Role: primary

yurdaguel.zopf@k-erlangen.de

+49 9131 85-45218

Hans Joachim Herrmann, Dr. oec. troph.

Role: backup

hans.herrmann@uk-erlangen.de

+49 9131 85-45017

Other Identifiers

EMS Tumor Motor Proteins

Identifier Type: -

Identifier Source: org_study_id